Delivery Order SPE2DB20D1109-SPE2DB21FP01U
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., covers the delivery of Vyvanse 20 mg capsules to the Defense Logistics Agency (DLA). The contract, valued at $1,335.39, is a delivery order under the company's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a ceiling value of up to $999,999,999.00 and runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a wide range of...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $3,671.84 for the supply of Vyvanse 30 mg capsule. The award was made by the Defense Logistics Agency (DLA), a defense agency, and is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order (DO) under an Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical. The award, valued at $1,607.38, is for the supply of Vyvanse 10 mg capsules to support federal healthcare programs. The IDC, worth up to $999,999,999.00, provides a comprehensive range of pharmaceutical products and medical supplies to the Department of Defense (DoD) and other...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Vyvanse 40 mg capsules. The $3,963.97 Firm Fixed Price delivery order falls under an Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for Amerisourcebergen to supply a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 60 mg capsules. The contract, valued at $1,664.19, is a delivery order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, worth up to $999,999,999.00, serves as the primary vehicle for AmerisourceBergen to deliver a comprehensive...
- This federal contract award is for the delivery of 4,539,709,753 units of Vyvanse 60 mg capsules to the Medical Supply Chain division of the Defense Logistics Agency (DLA). The $12,072.26 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. This order does not have a set-aside designation. Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a significant supplier of prescription medications,...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, for the delivery of Vyvanse 20 mg capsules. The $17,302.68 firm fixed-price delivery order falls under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to provide a...
- This federal contract award, issued by the Defense Logistics Agency (DLA), is a delivery order valued at $1,468.54 for the pharmaceutical product Vyvanse 10 mg capsules. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen holds with the DLA Troop Support Medical, running through November 2026. This IDC...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $2,792.64 issued by the Defense Logistics Agency (DLA) for the supply of 4,553,492,506 units of VYVANSE 40 MG CAPSULE 100S. The award has no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., involves the delivery of pharmaceutical products and medical supplies to the Defense Logistics Agency (DLA) Troop Support Medical. The award, valued at $1,586.26, is for the supply of Vyvanse 60 mg capsules. This is a delivery order contract with a firm-fixed price pricing type and no set-aside designation. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB21FP01UDelivery Order
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order (SPE2DB21FP01U) valued at $15,301.92 for the supply of Vyvanse 60 mg capsules. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and does not have a set-aside designation, indicating open competition. Amerisourcebergen is a major pharmaceutical distributor that serves as a critical supplier to various government agencies, particularly the Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare systems. The company holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which runs through December 2025. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the DoD worldwide. Additionally, Amerisourcebergen maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.3k | 4/13/21 |